Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • cancer therapy

    Tag: cancer therapy

    You Searched For "cancer therapy"
    Merck to spin-off  biosimilar drugs business to focus on Keytruda

    Merck to spin-off biosimilar drugs business to focus on Keytruda

    Medical Dialogues Bureau7 Feb 2020 9:15 AM IST
    Merck will retain its cancer drugs, including blockbuster cancer therapy Keytruda, vaccines, hospital and animal health businesses, the company...
    Natco Pharma settles patent litigation over generic version of anti-cancer drug Kyprolis

    Natco Pharma settles patent litigation over generic version of anti-cancer drug Kyprolis

    Medical Dialogues Bureau30 May 2019 5:12 PM IST
    Kyprolis is the trade name for the generic drug Carfilzomib. The anti-cancer drug is a targeted therapy and is classified as a Proteasome Inhibitor....
    Shilpa Medicare gets USFDA nod for Irinotecan injection to treat cancer

    Shilpa Medicare gets USFDA nod for Irinotecan injection to treat cancer

    Farhat Nasim17 May 2019 1:45 PM IST
    Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum, the company added. NEW DELHI: Shilpa...
    Intas Pharma launches Cancer Drug Eleftha for Rs 19,995; 65 percent lower than market rate

    Intas Pharma launches Cancer Drug Eleftha for Rs 19,995; 65 percent lower than market rate

    Meghna A Singhania11 April 2019 10:50 AM IST
    Mumbai: In a move that will provide relief to cancer patients, drugmaker Intas Pharmaceuticals has recently announced the launch of Trastuzumab...
    Unichem Labs gets USFDA nod to market Allopurinol tablets

    Unichem Labs gets USFDA nod to market Allopurinol tablets

    Farhat Nasim15 March 2019 9:35 AM IST
    Allopurinol tablets will be commercialised from company's Ghaziabad plant, Unichem Laboratories said.New Delhi: Drug firm Unichem Laboratories...
    Novartis Kymriah wins UK backing after initial lymphoma snub

    Novartis Kymriah wins UK backing after initial lymphoma snub

    Medical Dialogues Bureau3 Feb 2019 10:00 AM IST
    "Today's positive announcement regarding access to Kymriah treatment in England and Wales was secured as a result of our close working collaboration...
    GSK bets on pioneering cancer therapy with Adaptimmune deal

    GSK bets on pioneering cancer therapy with Adaptimmune deal

    Ruby Khatun Khatun9 Sept 2017 9:32 AM IST
    LONDON: GlaxoSmithKline (GSK) said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology,...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok